Why do some breast cancer patients quit hormone therapy? new study aims to find out

NCT ID NCT07180914

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This observational study will follow 300 premenopausal women with HR-positive early breast cancer who are already receiving ovarian function suppression (OFS) therapy as part of their routine care. Researchers want to see how many patients stop OFS within two years and why, and whether the length of treatment affects cancer outcomes. The goal is to improve long-term treatment adherence and prognosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ovarian Function Suppression (OFS) therapy
What this could lead to
If successful, this study could help doctors understand why some patients stop OFS therapy and how treatment duration affects breast cancer recurrence, leading to better support strategies.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient differences and real-world factors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.